|
Punjab FDA directs zonal officers to track manufacture and sale of seven H and H1 drugs
|
|
Peethaambaran Kunnathoor, Chennai
March 05 , 2025
|
|
|
Following information received by the Drugs Control Wing under the Food and Drugs Administration (FDA) in Punjab about misuse of seven H and H1 drug formulations for intoxication, the drug control wing has wanted all the regulatory officers to track the movement of these particular medicines in the market.
The officers should collect the details from the manufacturing companies as well as from the offices of the C&FAs, wholesalers and retailers about the movement of these drugs in the state.
According to Sanjiv Kumar Garg, joint commissioner for drugs control under the FDA, the drug formulations of concern, now under surveillance of the department, are pregabalin-300 mg, gabapentin-400, dicyclomine, tapentadol, zopiclone, flupentixol and carisoprodol.
Talking to Pharmabiz, Sanjiv Kumar said his office has received secret information that these drugs are misused by people including youth for intoxication. These drugs have to be sold on a valid prescription by medical doctors. The department has decided to monitor the marketing of the drugs by taking care that the genuine patients should not get affected by the non-availability of these medicines.
On the basis of the information received by the department, the health secretary has called a meeting of stakeholders including associations of Punjab drug manufacturers, C&FAs, wholesalers and retailers and assessed the situation of proliferation of these intoxicated drugs. Accordingly, the drug manufacturers have been instructed to report to the concerned drug control office about the sale of any of these drug formulations. They should also inform whether drugs are manufactured in tablet form or capsule form or in any other dosage forms, and the number of units they produced and marketed.
According to Kumar, who is the drug controller, the manufacturers should inform the concerned drug control office the complete details about the manufacturing of any of these drug formulations. Further, if a marketer or distributor buys 5,000 units or above, the manufacturer should intimate the details of the marketer to the nearest drug control office.
In the case of C&FAs, they should intimate to the office of the concerned drugs control officer the details of the wholesalers who purchase above 2,000 units. Similarly, the wholesale chemists should also intimate to the concerned drug control offices about those who purchase above 2,000 units of tablets, capsules or other dosage forms.
The retail chemists have been informed to report to the concerned office details about those people who buy 20 units or more than 20 units of these drugs.
The manufacturers, C&Fs, wholesalers and retailers should submit these data on the 7th day of every month to the concerned ADC offices.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|